All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, Should ruxolitinib become standard of care for steroid-dependent or refractory chronic GvHD?
The standard first-line treatment for chronic GvHD includes systemic corticosteroids; however, patients who become steroid-dependent or refractory require additional treatments. Here, Zeiser reports the findings from the phase III REACH3 study on ruxolitinib versus best available therapy in patients with steroid-dependent or refractory chronic GvHD.
Read a summary of the phase III REACH3 study, here.
Subscribe to get the best content related to GvHD delivered to your inbox